The European Patent Office (EPO) has decided that the European patent on mutations in breast and ovarian cancer susceptibility (EP 705903) is to be maintained in amended form.
Related Articles
Editorial
Fake drugs pose a threat to Europe’s cancer patients
Senza categoria
Health rationing in Europe: can cancer get a fair hearing?
Drug Watch
Leave a Reply